23:07 , Mar 20, 2019 |  BioCentury  |  Finance

Flagship prepares for scale

With its newly closed $824 million Special Opportunities Fund II, Flagship Pioneering has deepened its pool of capital to invest in its portfolio companies as they seek to scale up with multiproduct platforms. Upon the...
02:47 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
00:49 , Feb 16, 2019 |  BioCentury  |  Emerging Company Profile

NodThera: Inhibiting the inflammasome for NASH

NodThera Ltd. is tackling both the inflammation and fibrosis that drive NASH by inhibiting the NLRP3 inflammasome, a target few companies have interrogated for the indication. With a £28 million ($37 million) series A led...
22:50 , Feb 15, 2019 |  BioCentury  |  Finance

5AM seizes a new Opportunity

Alongside its newly closed sixth traditional venture fund, 5AM Ventures created its inaugural co-investment Opportunities I fund to give the firm more cash to participate in later venture rounds of its existing portfolio companies. According...
18:40 , Feb 15, 2019 |  BC Week In Review  |  Financial News

5AM raises nearly $500M for pair of funds

5AM Ventures said it closed its 5AM Opportunities I fund and 5AM Ventures VI fund, raising a total of $497 million. Opportunities I, 5AM's inaugural co-investment fund, raised $147 million to invest in the firm's...
18:21 , Feb 15, 2019 |  BC Week In Review  |  Financial News

Vor Biopharma raises $42M series A round

PureTech Health plc (LSE:PRTC) affiliate Vor Biopharma Inc. (Boston, Mass.) raised $42 million in a series A round led by 5AM Ventures and RA Capital to support development of the company's engineered hematopoietic stem cells...
14:57 , Feb 14, 2019 |  BC Extra  |  Financial News

Vor Biopharma raises $42M series A round

PureTech Health plc (LSE:PRTC) affiliate Vor Biopharma Inc. (Boston, Mass.) raised $42 million in a series A round led by 5AM Ventures and RA Capital to support development of the company's engineered hematopoietic stem cells...
05:05 , Feb 13, 2019 |  BC Extra  |  Financial News

5AM raises nearly $500M for pair of funds

5AM Ventures said it closed its 5AM Opportunities I fund and 5AM Ventures VI fund, raising a total of $497 million. Opportunities I, 5AM's inaugural co-investment fund, raised $147 million to invest in the firm's...
19:35 , Jan 24, 2019 |  BC Innovations  |  Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks. Cabaletta spun...
17:25 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Digital therapeutics company Pear closes $64M series C round

Pear Therapeutics Inc. (Boston, Mass.) raised $64 million in a series C round to support commercialization of its reSET digital therapeutic portfolio and fund its clinical pipeline. In November, Pear and partner Sandoz Ltd. launched...